✅ Product Benefits

• Dual-action JAK inhibition: Tofacitinib selectively inhibits Janus kinases (JAK1 and JAK3), modulating immune cell signaling pathways to reduce inflammation and tissue damage in autoimmune diseases like rheumatoid arthritis and ulcerative colitis .

• Once-daily dosing: The extended-release formulation allows for convenient once-daily administration, improving patient adherence to treatment regimens .

• Versatile indications: Approved for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) .

• Flexible use: Can be used as monotherapy or in combination with other DMARDs, depending on the patient's condition and treatment response .

• Established efficacy: Clinical studies have demonstrated the effectiveness of tofacitinib in reducing symptoms and improving quality of life in patients with these chronic inflammatory conditions .

ℹ️ Precautions & Safety Notes

• Increased risk of infections: Tofacitinib may suppress the immune system, increasing the risk of serious infections, including tuberculosis, bacterial, fungal, and viral infections. Patients should be screened for infections before starting treatment and monitored during therapy .

• Blood clots and cardiovascular events: There is an increased risk of blood clots, including pulmonary embolism, and cardiovascular events, particularly in patients with existing risk factors. Regular monitoring is recommended .

• Liver enzyme elevations: Liver function tests should be performed before starting treatment and periodically thereafter, as tofacitinib can cause elevations in liver enzymes .

• Renal and hepatic impairment: Dose adjustments are necessary for patients with moderate to severe renal or hepatic impairment. The recommended dose is tofacitinib 5 mg once daily in such cases .

• Pregnancy and breastfeeding: Tofacitinib is classified as a Category C drug during pregnancy, indicating that risk cannot be ruled out. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether tofacitinib is excreted in human breast milk; therefore, caution should be exercised when administered to a nursing mother .

• Drug interactions: Tofacitinib is metabolized by cytochrome P450 enzymes, and concomitant use with strong CYP3A4 inhibitors or inducers can affect its plasma concentrations. Dose adjustments may be necessary when used with such agents .

• Contraindications: Tofacitinib is contraindicated in patients with known hypersensitivity to tofacitinib or any component of the formulation. It should not be used in combination with biological DMARDs or potent immunosuppressants .